Norelgestromin is a progestin used as the progestational component of a transdermal combined hormonal contraceptive, preventing pregnancy primarily through suppression of ovulation. It is administered transdermally in combination with the estrogen ethinyl estradiol, delivering both hormones systemically over a 7-day wear period.
- Mechanism
- Curator reviewed
Norelgestromin inhibits estrone sulfatase, which converts sulfated steroid precursors to estrogen during pregnancy. Norgelgestromin/ethinylestradiol suppresses follicular development, induces changes to the endometrium, which decreases chances of implantation and thickens the cervical mucus, impeding sperm swimming into the uterus. It also has similar agonisting binding affinities as its parent compound, Norgestimate, for progesterone and estrogen receptors.
- Formula / weight
- C21H29NO2 · 327.468 g/mol (avg)
- First approval
- Canada, 2002 · United States, 2001 · European Union, 2020
- Also known as
- 17-Deacetylnorgestimate · 17-Deacylnorgestimate · D-Norgestrel 3-oxime · Deacetylnorgestimate · Levonorgestrel 3-oxime
- Code names
- BRN 4202099 · RWJ 10553
- Brand names
Resolves to
ISHXLNHNDMZNMC-XUDSTZEESA-NSMILES[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(C=C3CC[C@@]21[H])=NOWhat you can answer from here — as of September 13, 2026
Which drugs share a target with Norelgestromin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account